Get the Stockscreener App
4.85
3.19%
-0.16
Pre-market:
5.00
0.15
+3.09%
Plus Therapeutics Inc stock is traded at $4.85, with a volume of 290.49K.
It is down -3.19% in the last 24 hours and down -7.62% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$5.01
Open:
$5.13
24h Volume:
290.49K
Relative Volume:
0.18
Market Cap:
$33.39M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.1512
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
-12.30%
1M Performance:
-7.62%
6M Performance:
+676.50%
1Y Performance:
+1,445%
1-Day Range:
$4.79
$5.21
1-Week Range:
$4.79
$5.78
52-Week Range:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
4.85 | 33.39M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
PSTV Maintained by Ascendiant Capital -- Price Target Lowered to $57.00 - GuruFocus
[EFFECT] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics Launches New At-The-Market Equity Program - The Globe and Mail
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Material Definitive Agreement – June 2026 - Minichart
Plus Therapeutics Launches $17.35 Million ATM Equity Program With Canaccord Genuity - TradingView
Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program - Stock Titan
Plus Therapeutics (PSTV) adds Form of Indenture to S-3/A filing - Stock Titan
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform - Yahoo Finance
CNSide Diagnostics receives laboratory accreditation from CAP By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory - The Manila Times
CNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical Laboratory - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) launches $17.35M ATM with Canaccord - Stock Titan
Plus TherapeuticsMay Offer And Sell Up To $100 Million Of Securities From Time To TimeSEC Filing - TradingView
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PSTV Should I Buy - Intellectia AI
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
PLUS THERAPEUTICS (PSTV) Holds Near Support as Modest Gains PersistDefined Outcome ETF - thelegaladvocate.com
Plus Therapeutics (PSTV) Highlights Economic Benefits of Early D - GuruFocus
Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform - marketscreener.com
Plus Therapeutics study shows CNSide may cut LM costs by 40% - Investing.com Nigeria
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting - Quiver Quantitative
Plus' CNSide Diagnostic Platform Demonstrates Substantial - GlobeNewswire
PSTV Technical Analysis | Trend, Signals & Chart Patterns | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $12 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Total equity of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net current asset value per share of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total common shares outstanding of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total debt of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net margin % of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics Stockholders Back Directors and Incentive Plan - TipRanks
Number of shareholders of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics (PSTV) Forms Strategic Alliance with Ephemeral Technologies - GuruFocus
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics partners with Ephemeral on AI platform By Investing.com - Investing.com South Africa
Plus Therapeutics, Inc. Cash Flow – DUS:XMP1 - TradingView
Plus Therapeutics partners with Ephemeral on AI platform - Investing.com
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - The Manila Times
Plus Therapeutics, Inc. Statistics – DUS:XMP1 - TradingView
Plus Therapeutics, Inc. Earnings and Revenue – DUS:XMP1 - TradingView
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ANDREWS RONALD ASBURYmoomoo - Moomoo
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Equity grants for PLUS THERAPEUTICS (PSTV) director An van Es-Johansson - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU awards - Stock Titan
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):